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Objectives: We investigated whether Acinetobacter baumannii isolates of veterinary origin shared common
molecular characteristics with those described in humans.
Methods: Nineteen A. baumannii isolates collected in pets and horses were analysed. Clonality was studied
using repetitive extragenic palindromic PCR (rep-PCR) and multilocus sequence typing (MLST). PCR and DNA
sequencing for various b-lactamase, aminoglycoside-modifying enzyme, gyrA and parC, ISAba1 and IS1133,
adeR and adeS of the AdeABC efflux pump, carO porin and class 1/2/3 integron genes were performed.
Results: Twomain clones [A (n¼8) andB (n¼9)]wereobserved by rep-PCR.MLST indicated that cloneAcontained
isolates of sequence type (ST) ST12 (international clone II) and clone B contained isolates of ST15 (international
clone I). Two isolates of ST10 and ST20 were also noted. Seventeen isolates were resistant to gentamicin, 12 to
ciprofloxacin and 3 to carbapenems. Isolates of ST12 carried blaOXA-66, blaADC-25, blaTEM-1, aacC2 and IS1133.
Strains of ST15 possessed blaOXA-69, blaADC-11, blaTEM-1 and a class 1 integron carrying aacC1 and aadA1.
ISAba1 was found upstream of blaADC (one ST10 and one ST12) and/or blaOXA-66 (seven ST12). Twelve isolates
of different STs contained the substitutions Ser83Leu in GyrA and Ser80Leu or Glu84Lys in ParC. Significant disrup-
tions of CarO porin and overexpressed efflux pumps were not observed. The majority of infections were hospital
acquired and in animals with predisposing conditions for infection.
Conclusions: STs and the molecular background of resistance observed in our collection have been frequently
described in A. baumannii detected in human patients. Animals should be considered as a potential reservoir
of multidrug-resistant A. baumannii.
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Introduction
Acinetobacter baumannii is an opportunistic pathogen that is dif-
ficult to treat due to its ability to express multiple intrinsic and
acquired mechanisms that make the organism frequently
multidrug-resistant (MDR) to antibiotics.1 Production of acquired
class A extended-spectrum b-lactamases (ESBLs), class B and/or
class D carbapenemases (e.g. IMP and VIM types and OXA-23,
-24/40 and -58), overexpression of chromosomal enzymes
(i.e. ADCs and OXA-Ab) and efflux pumps (e.g. AdeABC), loss of
outer membrane proteins (OMPs; e.g. CarO), altered penicillin
binding proteins, production of aminoglycoside modifying
enzymes (AMEs) or 16S RNA methylases and mutations in the
quinolone resistance-determining region (QRDR) of the gyrA
and parC genes are common mechanisms of resistance found
in A. baumannii clinical isolates. The organism can also easily
survive in hospital environments.2–4
A. baumannii is commonly responsible for nosocomial infec-
tions in immunocompromised and severely ill patients who
undergo extended medical and invasive procedures. High
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morbidity and mortality rates have been reported during out-
breaks observed in hospitals and long-term care facilities in
different countries.1,5–7 On the basis of various typing analyses,
three main clusters have been associated with the A. baumannii
pandemic (i.e. European clone types I, II and III).3,8–10 More
recently, a large multilocus sequence typing (MLST) analysis
has shown that the majority of clinical A. baumannii isolates
found in US military medical facilities and European hospitals
were included in three lineages; the first contained the most pre-
dominant sequence type (ST) ST11 and its single-locus variants
ST1/10/12/47, the second consisted of ST15/16/45/46 and the
third most predominant ST was ST8/14. These three clusters cor-
respond to the European clones II, I and III, respectively.11 These
lineages are now more appropriately called ‘international clones’,
as they are spreading not only in Europe, but also in other parts
of the world.12
Infections due to A. baumannii have been rarely reported in
animals and only a few studies have described this occur-
rence.3 In 2000, Vaneechoutte et al.13 identified seven
A. baumannii isolates from jugular catheter tips placed in
horses, but the organism was only indicated as responsible
for local infection or colonization. In the same period at the
University of Bern, Francey et al.14 described the clinical charac-
teristics of several pets with various A. baumannii infections (i.e.
urinary, respiratory, wound and bloodstream infections), report-
ing an overall attributable mortality of 47% [100% in the inten-
sive care unit (ICU)]. At the same time it was noted that: (i) A.
baumannii isolates collected in 1998–2000 from pets and
horses were included in two main PFGE clones;15 (ii) these
organisms may be responsible for rapidly progressing fatal sys-
temic infections such as sepsis and fasciitis;16 and (iii) the
majority of A. baumannii infections were hospital acquired.14,15
Since a detailed molecular analysis of isolates was not per-
formed in the above investigations, data regarding A. baumannii
of veterinary origin are still lacking.3 Herein, we report the first
analysis of the antibiotic susceptibility profile, genetic determi-
nants of resistance and clonality of a collection of A. baumannii
isolates responsible for infections in pets and horses.
Materials and methods
Clinical isolates and susceptibility testing
A. baumannii isolates were collected from clinical samples of animals
received by the Center for Zoonoses, Bacterial Animal Diseases and
Antibiotic Resistance (ZOBA) of Bern (Switzerland) from May 2004
through August 2009. Species identification and antimicrobial suscepti-
bility tests were routinely assessed using the Vitek 2 system (bioMe´rieux
Inc.). Identification was confirmed with matrix-assisted laser deso-
rption/ionization time of flight (MALDI-TOF) mass spectrometry
(Bruker Daltonik) and detection of the chromosomal blaOXA-Ab genes
(formerly blaOXA-51-like; see below),
4 whereas the MICs were determined
by microdilution in Mueller–Hinton broth (BBL, Becton Dickinson) using
Sensititre ESB1F plates (Trek Diagnostic Systems, Inc.). Susceptibility
results were interpreted according to the current European Committee
on Antimicrobial Susceptibility Testing (EUCAST) criteria.17 MICs
were also determined in the presence of the efflux pump inhibitor
phenyl-arginine-b-naphthylamide (PAbN; Sigma) at a final concen-
tration of 40 mg/L.
Analysis of clonality
The genetic relatedness among the A. baumannii isolates was
determined using the repetitive extragenic palindromic PCR (rep-PCR).
Genomic DNA was obtained with a peqGOLD Bacterial DNA Kit (Peqlab).
PCR amplification reactions were performed using the REP1 and REP2
degenerate primers and Expand Long Template Taq DNA Polymerase
Mix (Roche) as described by Vila et al.18 Amplification conditions were
as follows: 10 min at 948C; 32 cycles of denaturation (1 min at 948C),
annealing (1 min at 438C) and extension (6 min at 728C); and a final
extension of 12 min at 728C. Rep-PCR products were separated by elec-
trophoresis using the Agilent 2100 Bioanalyzer (Agilent Technologies),
yielding profile bands for each strain. Band patterns were aligned using
2100 Expert software (Agilent Technologies) and interpreted using BioNu-
merics software version 5.1 (Applied Maths).
The T5000TM Biosensor System (Ibis Biosciences Inc., a subsidiary of
Abbott), a PCR electrospray ionization mass spectrometry (PCR/ESI-MS)
platform, was used to perform a form of MLSTanalysis of all A. baumannii
isolates. As previously reported, the Acinetobacter genotyping kit uses
eight primer pairs to target six housekeeping genes (i.e. efp, trpE, adk,
mutY, fumC and ppa).11
Molecular methods
PCR and DNA sequence analyses for b-lactamase genes (i.e. blaADC,
blaOXA-Ab and other acquired blaOXAs, blaTEM, blaSHV, blaCTX-M, blaPER,
blaGES, blaVEB, blaIMP and blaVIM), AME genes (i.e. aphA6, aadA1, aadB,
aacC1 and aacC2), ISAba1 and IS1133 insertion elements, regulatory
genes of the AdeABC efflux pump (i.e. adeR and adeS), the carO porin
gene, class 1/2/3 integrases and class 1 integron resistance gene(s) cas-
sette were performed using primers and conditions previously pub-
lished.19–23 Detection of the ISAba1 element upstream of the blaADC
and blaOXA-Ab genes was carried out as described previously.
24,25
Genetic analysis of the QRDR of gyrA and parC genes was also done.26
DNA traces were analysed using Sequencher 4.10.1 (Gene Codes Corpor-
ation) and translated into a protein sequence when necessary using the
ExPASy Proteomic Server (www.expasy.ch/). The resulting protein
sequences were compared with amino acid translated DNA reference
sequences CP000863 for CarO, X82165 for GyrA, X95819 for ParC and
AY426969 for AdeR and AdeS of A. baumannii.
Analytical isoelectric focusing (aIEF)
Detection of b-lactamases was performed by using aIEF as previously
reported.27,28 One well-characterized Klebsiella pneumoniae isolate
(i.e. VA367) producing TEM-1, KPC-2, SHV-11 and SHV-12 b-lactamases
and one Escherichia coli strain (i.e. 9217/10) expressing CMY-2
b-lactamase were used as controls.28
Clinical data
Clinical records of animals developing infection due to A. baumannii and
admitted to the Equine Clinic and the Small Animal Hospital (University of
Bern, Switzerland) were examined retrospectively. The two clinics are
situated approximately 200 m apart. The following data were recorded:
age; underlying diseases; predisposing conditions of infection (e.g. use
of corticosteroids, intravascular catheters and antibiotic use) when
present for at least 1 week before the A. baumannii isolation; and anti-
microbial agents administered during the infectious episode. History of
hospitalizations and prior use of antibiotics were also taken into
account. An infection that occurred at least 48 h after the admission of
the animal to the veterinary hospital was defined as hospital acquired,
otherwise it was defined as community acquired.




A. baumannii isolates and analysis of genetic relatedness
Nineteen A. baumannii isolates collected from dogs (n¼12),
horses (n¼4) and cats (n¼3) were analysed. As shown in
Figure 1, the majority of A. baumannii were grouped into two
clones [i.e. clone A (n¼8) and clone B (n¼9)] that share
,60% band pattern homology, whereas two isolates were
not related to the above clones. Further MLST analysis by
PCR/ESI-MS indicated that clone A contained isolates of ST12
(international clone II) and clone B included isolates of ST15
(international clone I); the remaining two isolates were ST10
(a single-locus variant of ST12) and ST20.11
Since 2002 A. baumannii isolates of ST10, ST12 and ST15,
along with ST11, ST14 and ST24, have been frequently reported
as being responsible for bloodstream infection and skin coloniza-
tion in military and civilian patients admitted to US medical






























































Figure 1. Results of rep-PCR and MLST analyses for the 19 A. baumannii isolates responsible for infection in animals (12 dogs, 4 horses and 3 cats).
rep-PCR identified two main clones (A and B) that shared ,60% band homology. Isolates included in clone A showed 100% band homology, whereas
those included in clone B demonstrated slightly different band patterns. By using MLST, isolates included in clone A were ST12 (international clone II),
whereas those in clone B were ST15 (international clone I). Two A. baumannii isolates were ST10 (a variant related to ST12) and ST20.
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the spread and the clinical impact of carbapenem-resistant
A. baumannii isolates of ST10 and ST12 across a six-hospital
healthcare system in northeast Ohio. It should also be noted
that A. baumannii isolates belonging to international clones I
and II are found all over the world, including the countries sur-
rounding Switzerland.8,30–32
Overall, our data indicate that two lineages of A. baumannii
isolates that are spreading worldwide among patients are also
found among hospitalized animals in Switzerland (see clinical
information in Table S1, available as Supplementary data at
JAC Online). We speculate that these two clonal lineages might
be identical to those observed in pets hospitalized at our insti-
tution in 1998–2000 and that subsequently disappeared after
thorough cleaning and disinfection of the ICU.15 Unfortunately
those A. baumannii isolates were not available for comparison
using rep-PCR and MLST. Furthermore, we were not able to
provide information regarding the clinical and/or travel history
of the animal owners or the geographic origin of the pets and
horses.
Phenotypic and molecular characterization of drug
resistance genes
Table 1 summarizes the antibiotic phenotypes and the genetic
basis of resistance of the 19 A. baumannii isolates. Overall, 17
isolates were resistant to gentamicin, 12 were resistant to cipro-
floxacin and 3 were non-susceptible to carbapenems.17
All A. baumannii isolates were susceptible to amikacin,
indicating that they did not produce 16S rRNA methylases.33
The two isolates of ST10 and ST20 were susceptible to aminogly-
cosides due to the lack of AME genes. In contrast, isolates of
ST12 possessed aacC2 (usually associated with IS1133),
whereas those of ST15 carried a class 1 integron with a
resistance gene cassette of 2.6 kb containing aacC1 and aadA1.
Furthermore, three isolates of ST15 also resistant to tobramycin
harboured aadB (Table 1). These genetic signatures of AMEs are
fully consistent with the aminoglycoside resistance patterns
observed in our isolates.34 We also noted that these specific
AME genes were previously reported in MDR A. baumannii isolates
of human origin.2,19,23 In particular, the 2.6 kb class 1 integron
resistance cassette was reported in several analyses performed
in different countries,23,35–38whereas the aacC2 gene associated
with IS1133 may be part of a residual class 1 integron
with a truncated integrase gene as previously described in one
A. baumannii detected in South Africa.39
Twelve A. baumannii isolates of different STs were resistant to
ciprofloxacin due to amino acid substitutions in the GyrA and
ParC proteins. In particular, 11 of the 12 isolates contained
both Ser83Leu in GyrA and Ser80Leu in ParC substitutions,
whereas strain Km1492-04 possessed the Ser83Leu in GyrA
along with Glu84Lys in ParC (Table 1). While substitutions at
Ser83 of GyrA and Ser80 of ParC are frequently detected
among quinolone-resistant A. baumannii, substitutions at Glu84
of ParC are more rarely reported.26,40–42 We hypothesize that
the high prevalence (i.e. 63.2%) of quinolone resistance in differ-
ent lineages of A. baumannii could be due to the frequent use of
enrofloxacin and marbofloxacin in veterinary medicine (as also
observed in our clinical cases; see Table S1).43
The carO gene was found intact in all A. baumannii isolates
(i.e. insertion elements were not observed). When compared
with the reference sequence CP000863, the CarO porin of iso-
lates belonging to ST10, ST12 and ST20 did not show amino
acid substitutions, whereas isolates belonging to ST15 showed
one or two amino acid variations (Table 1). These substitutions
are most likely the result of normal allelic variations between
clone types and probably have little effect on the function of
the OMP. With regard to the AdeABC efflux pump, all 19 A. bau-
mannii possessed the adeR gene, whereas the adeS was not
amplified from isolates of international clone II (n¼9). The lack
of adeS was previously linked to increased susceptibility to ami-
noglycosides due to its essential action for the expression of
the adeABC operon.22 Analysis of 19 adeR and 10 adeS translated
amino acid sequences did not reveal substitutions previously
associated with increased resistance (i.e. Pro116Leu for AdeR
and Thr153Met for AdeS).22 In addition, the MIC values of
tested antibiotics did not show a significant decrease when the
efflux inhibitor PAbN was added (data not shown). Overall, the
above results indicate that all A. baumannii isolates most likely
have functional CarO porins and did not possess overexpressed
efflux systems such as the AdeABC pump.
Further molecular and biochemical analyses showed that the
A. baumannii isolates produced several b-lactamases. In particu-
lar, isolates of ST12 carried blaOXA-66, blaADC-25 and blaTEM-1 (only
Km1016-09 was blaTEM-negative), whereas those of ST15 pos-
sessed blaOXA-69, blaADC-11 and blaTEM-1. The expression of the
bla genes found in our collection was in part supported by the
aIEF results (i.e. TEM-1, pI of 5.4; OXA-Ab, pI of 6.5; and
ADCs, pI of 9.0). Other bla genes encoding for acquired ESBLs
(e.g. PER, VEB and GES types) or carbapenemases (e.g. OXA-23,
-24/40 and -58) were not detected. It should also be noted
that in using the ESB1F microdilution panel, synergy between cla-
vulanate and cefotaxime or ceftazidime was not observed, indi-
cating the plausible absence of other ESBLs (data not shown).
Two A. baumannii isolates (i.e. Km410-05 and Km765-04)
possessed the ISAba1 element upstream of blaADC (Table 1). As
previously reported,24 ISAba1 augments the expression level of
ADCs, and this is consistent with the higher MIC values for
extended-spectrum cephalosporins and piperacillin/tazobactam
observed in these two isolates. ISAba1 is also usually able to
increase the expression level of the chromosomal OXA-Ab carba-
penemase when upstream of this bla gene.25 However, only two
(i.e. Km410-05 and Km1016-09) of the seven A. baumannii
possessing this IS element had MICs for imipenem and/or mero-
penem (i.e. MICs of 4–8 mg/L) in the resistant range. This is par-
tially in contrast with other reports where the MICs for
carbapenems were more significantly increased (e.g. MICs
.8 mg/L).23,25,40 We speculate that in our A. baumannii isolates
this phenomenon is due to the absence of further mechanisms
of resistance (e.g. porin loss and increased expression of efflux
pumps). In fact, isolates of human origin usually possess mul-
tiple mechanisms of resistance that contribute to carbapenem
resistance.23,40
Clinical data of infected animals
As shown in Table S1, infections due to A. baumannii in animals
were commonly hospital acquired and involved various body
sites (with a slight preponderance of wound infections and
abscesses). About half of infected animals had a previous
history of hospitalization, whereas the majority of them had
A. baumannii in pets and horses
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Table 1. Molecular characterization of drug resistance genes and antibiotic susceptibility profile of the 19 A. baumannii isolates responsible for infection in pets and horses
Strain, STs IC aIEF (pI)
Molecular analysis of resistance genesa MIC (mg/L)b
blaOXA-Ab blaADC blaTEM ISAba1 IS1133 IntI aacC1 aadA1 aacC2 aadB GyrA ParC CarO CTX CAZ FEP TZP IPM MEM AMK GEN TOB CIP SXT TET PolB
Km1008-06, ST12 II 9.5, 5.4 OXA-66 ADC-25 TEM-1 +c + 2 2 2 + 2 Ser83Leu Ser80Leu ¼ 4 4 4 ≤4 ≤0.5 ≤1 4 ≥32 4 ≥4 ≥320 ≥16 1
Km1016-09, ST12 II 9.5, 9.0, 6.5 OXA-66 ADC-25 — +c + 2 2 2 + 2 Ser83Leu Ser80Leu ¼ 4 2 4 32 8 8 ≤2 ≥32 ≤1 ≥4 ≥320 ≥16 1
Km1022-06, ST12 II 9.5, 5.4 OXA-66 ADC-25 TEM-1 +c + 2 2 2 + 2 Ser83Leu Ser80Leu ¼ 4 2 4 ≤4 ≤0.5 ≤1 4 ≥32 4 ≥4 ≥320 ≥16 1
Km408-05, ST12 II 9.5, 5.4 OXA-66 ADC-25 TEM-1 +c + 2 2 2 + 2 Ser83Leu Ser80Leu ¼ 8 4 8 16 ≤0.5 ≤1 ≤2 ≥32 ≤1 ≥4 40 ≥16 1
Km58-05, ST12 II 9.5, 5.4 OXA-66 ADC-25 TEM-1 +c + 2 2 2 + 2 Ser83Leu Ser80Leu ¼ 4 4 8 8 ≤0.5 ≤1 ≤2 ≥32 ≤1 ≥4 40 ≥16 1
OD474-06, ST12 II 9.5, 6.5, 5.4 OXA-66 ADC-25 TEM-1 +c + 2 2 2 + 2 Ser83Leu Ser80Leu ¼ 64 64 16 32 1 ≤1 ≤2 ≥32 ≤1 ≥4 40 ≥16 0.5
Km410-05, ST12 II 9.5, 6.5, 5.4 OXA-66 ADC-25 TEM-1 +c,d + 2 2 2 + 2 Ser83Leu Ser80Leu ¼ ≥128 64 16 ≥128 4 4 ≤2 ≥32 ≤1 ≥4 160 ≥16 1
Km875-06, ST12 II 9.5, 5.4 OXA-66 ADC-25 TEM-1 + 2 2 2 2 + 2 Ser83Leu Ser80Leu ¼ 8 4 8 8 ≤0.5 ≤1 4 ≥32 4 ≥4 ≥320 ≥16 1
Km765-04, ST10 II 9.5, 6.5 OXA-66 ADC-25 TEM-1 +d 2 2 2 2 2 2 Ser83Leu Ser80Leu ¼ ≥128 64 16 ≥128 2 ≤1 4 ≤4 ≤1 ≥4 ≥320 ≥16 1
Km693-07, ST20 NI 9.5 OXA-95 ADC-26 TEM-1 2 2 2 2 2 2 2 ¼ ¼ ¼ 8 4 2 ≤4 ≤0.5 ≤1 ≤2 ≤4 ≤1 ≤1 ≤ 20 ≤1 ≤0.25
Km323-09, ST15 I 9.5, 9.0, 6.5, 5.4 OXA-69 ADC-11 TEM-1 2 + +e + + 2 2 Ser83Leu Ser80Leu Ile74Leu,
Glu217Lys
8 4 8 32 8 4 ≤2 ≥32 ≤1 ≥4 ≤ 20 ≤1 0.5
Km732-08, ST15 I 9.0, 5.4 OXA-69 ADC-11 TEM-1 2 2 +e + + 2 2 Ser83Leu Ser80Leu Glu217Lys 4 2 4 ≤4 ≤0.5 ≤1 ≤2 ≥32 ≤1 ≥4 ≥320 ≥16 1
Km1492-04, ST15 I 9.0 OXA-69 ADC-11 TEM-1 2 2 +e + + 2 2 Ser83Leu Glu84Lys Ser214Thr 16 8 16 32 ≤0.5 ≤1 8 ≥32 2 ≥4 ≥320 ≥16 1
Km1245-05, ST15 I 9.0, 5.4 OXA-69 ADC-11 TEM-1 2 2 +e + + 2 2 ¼ ¼ Glu217Lys 8 4 8 ≤4 ≤0.5 ≤1 ≤2 ≥32 ≤1 ≤1 80 2 1
Km183-05, ST15 I 9.0, 5.4 OXA-69 ADC-11 TEM-1 2 2 +e + + 2 2 ¼ ¼ Glu217Lys 8 4 4 8 ≤0.5 ≤1 ≤2 ≥32 ≤1 ≤1 ≥320 ≥16 1
Km1887-04, ST15 I 9.0, 5.4 OXA-69 ADC-11 TEM-1 2 2 +e + + 2 2 ¼ ¼ Glu217Lys 8 4 4 ≤4 ≤0.5 ≤1 4 ≥32 ≤1 ≤1 ≥320 ≥16 1
Km456-05, ST15 I 9.0 OXA-69 ADC-11 TEM-1 2 2 +e + + 2 + ¼ ¼ Glu217Lys 2 1 4 ≤4 ≤0.5 ≤1 ≤2 ≥32 ≥16 ≤1 160 ≥16 1
Km1873-06, ST15 I 9.0, 5.4 OXA-69 ADC-11 TEM-1 + 2 +e + + 2 + ¼ ¼ Glu217Lys 4 2 8 ≤4 ≤0.5 ≤1 ≤2 ≥32 ≥16 ≤1 ≥320 ≥16 1
Km57-09, ST15 I 9.0, 5.4 OXA-69 ADC-11 TEM-1 2 2 +e + + 2 + ¼ ¼ Glu217Lys 4 4 4 ≤4 ≤0.5 ≤1 8 ≥32 ≥16 ≤1 ≥320 ≥16 1
IC, international clone; NI, not included among the three international clones; +, positive; 2, negative; CTX, cefotaxime; CAZ, ceftazidime; FEP, cefepime; TZP, piperacillin/tazobactam;
IPM, imipenem; MEM, meropenem; AMK, amikacin; GEN, gentamicin; TOB, tobramycin; CIP, ciprofloxacin; SXT, trimethoprim/sulfamethoxazole; TET, tetracycline; PolB, polymyxin B.
aCarO, GyrA and ParC proteins are reported with their amino acid substitutions, otherwise they are reported as equal (¼) to the reference sequences (i.e. CP000863, X82165 and
X95819, respectively). The remaining resistance genes tested (see the Molecular methods section) are not reported because they were not detected in any of the A. baumannii isolates.
bInterpretation of MICs according to 2011 EUCAST criteria (S, susceptible):17 TZP (criteria not available); CTX, CAZ and FEP (susceptibility testing not recommended); IPM and MEM
(S, ≤2 mg/L); AMK (S, ≤8 mg/L); GEN and TOB (S, ≤4 mg/L); CIP (S, ≤1 mg/L); SXT (S, ≤2/38 mg/L); TET (susceptibility testing not recommended); and PolB (S, ≤2 mg/L). Data regarding
AMK, TOB, SXT, TET and PolB were obtained using the Vitek 2 system.
cISAba1 was upstream of blaOXA-Ab.
dISAba1 was upstream of blaADC.











underlying diseases and risk factors that could favour opportu-
nistic infections such as those due to A. baumannii. Three
cases of systemic infection (i.e. those due to Km765-04,
Km1492-04 and Km474-06) resulted in death. We also noted
that several cases of hospital-acquired A. baumannii infection
occurred within a short period of time (e.g. five cases of ST12
during February–April 2005), suggesting a potential role for
nosocomial transmission through the environment and/or trans-
mission by hospital staff (Table S1).
Conclusions
This is the first molecular analysis of A. baumannii responsible for
infections in pets and horses using established methods pre-
viously used for human isolates. Our strains did not possess
any known acquired carbapenemase gene, loss of porin CarO
or overexpressed efflux system, but the molecular backgrounds
of resistance to aminoglycosides and quinolones and the hyper-
production of chromosomal b-lactamases had patterns
common to those described in A. baumannii of human origin.
More importantly, the two international clones persistently
found in animals admitted at our institutions during 2004–09
are often reported in civilian and military patients hospitalized
all over the world. The spread of such A. baumannii isolates in
companion animals is very concerning because in humans
these clonal lineages are associated with multiple mechanisms
of resistance, including those against ‘last-line’ antibiotics such
as carbapenems and colistin.5,29 Since the majority of animal
cases were hospital acquired and in subjects with common pre-
disposing conditions for infection compared with those reported
in humans (e.g. prolonged use of antibiotics), we advance that in
the near future A. baumannii isolates of veterinary origin could
acquire further mechanisms of resistance and evolve into patho-
gens that are more difficult to treat. Larger screening and epide-
miological studies should be planned to investigate the impact of
animals on the spread of MDR A. baumannii isolates among
humans.
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